GERON CORP APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
GERON CORP (GERN) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $13.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-05-06
- GERON CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $13.00K, a 13.33% decline year-over-year.
- GERON CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $15.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month |
|---|---|
| 2026-03-31 | $13.00K 10-Q · filed 2026-05-06 |
| 2025-03-31 | $15.00K 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |